• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Dual-function nanoparticles deliver anti-tumor compounds and track treatment efficacy  [PreClinical]

byChristine YoonandJessica Lau
June 18, 2016
in Oncology, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The authors designed reporter nanoparticles (RNPs) that 1) delivered a chemotherapeutic or immunotherapeutic agent and 2) emitted fluorescence when activated by the apoptosis enzyme caspase-3.

2. In several murine models of cancer, RNPs slowed tumor growth, differentiated between chemosensitive and chemoresistant tumors, and improved detection of early treatment response over traditional imaging methods.

Evidence Rating Level: 2 (Good)           

Study Rundown: Traditional imaging modalities such as computer tomography (CT) and positron emission tomography (PET) are used to measure responses to anti-tumor therapy. However, these approaches lack the sensitivity needed to detect early responses to treatment. Further, in the case of immunotherapy, they cannot distinguish between malignant tumor growth and growth associated with productive immune cell infiltration.

To address these limitations, the authors developed nanoparticles that can deliver a chemotherapeutic (paclitaxel) or immunotherapeutic (anti-PD-L1) agent and also generate a fluorescent signal in response to treatment-associated activation of the apoptosis pathway. In a mouse model of breast cancer, paclitaxel-containing RNPs reduced tumor growth rate and generated detectable fluorescence signals as early as 8 hours after therapy initiation. The RNPs were then tested in a second model, in which paclitaxel-sensitive and -resistant prostate cancer cell lines were implanted into mice. Paclitaxel-sensitive tumors displayed fluorescence activation within 12 hours after the first of two doses of RNPs. Immunohistochemistry analysis of the tumors confirmed an increase in caspase-3 within the chemosensitive tumors. Finally, using a mouse model of melanoma, the authors demonstrated that RNPs carrying anti-PD-L1 antibody successfully induced apoptosis, generated fluorescent signals, and initiated T cell infiltration into tumors. In contrast, CT and PET imaging of these RNP-treated mice did not detect any changes between the control and RNP-treated groups even one week after treatment.

This work demonstrated the capability for nanoparticles to be used as indicators of early therapeutic efficacy in addition to drug delivery vehicles. However, for this technology to be translated to the clinic, further studies demonstrating treatment efficacy and safety are necessary. More importantly, the RNPs must also be adapted for non-invasive imaging through deep tissues by using radiocontrast dyes in place of the fluorescent indicators.

Click to read the study in PNAS

RELATED REPORTS

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

Relevant Reading: Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent

In-Depth [animal study]: In the first in vivo experiment, 4T1 breast cancer cells were implanted into BALB/c mice 10 days before the initiation of RNP treatment. Compared to control nanoparticles with no paclitaxel, RNPs slowed the increase in relative tumor volume by ~50% after 11 days since the start of treatment. In mice treated with RNPs, tumors also generated significantly greater fluorescence signals relative to normal tissue over 8 days (p<0.05).

In the second mouse model, paclitaxel-sensitive (DU145) and -resistant (DU145TR) prostate cancer cell lines were injected into the right and left flanks, respectively, of BALB/c athymic mice. When evaluated 2 days after the second/final RNP dose was administered, DU145 tumors generated a ~400% increase in fluorescence whereas DU145TR tumors exhibited little to no change in fluorescence as compared to normal tissue. As expected, staining of the drug-sensitive and -resistant tumors after treatment revealed a qualitative increase in caspase-3 levels in DU145 tumors.

In the final in vivo model, B16/F10 melanoma cells were implanted into C57BL/6 mice 10 days before RNP treatment. When compared to control RNPs, anti-PD-L1 RNPs significantly increased fluorescence from tumors (p<0.05) and induced greater activation of caspase-3 as measured by Western blot of tumor tissue samples. Flow cytometry of isolated tumor cells illustrated a ~200% increase in the number of CD8+ T cells from tumors in RNP-treated animals relative to the control group (p<0.05). Imaging of these animals with PET with 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG-PET) and CT indicated no significant decreases in the uptake of [18F]FDG with RNP treatment, suggesting that traditional imaging modes for monitoring treatment efficacy were insensitive to the small changes in early response detected by RNPs.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

E-cigarette use may increase risk of smoking cigarettes in teens

Next Post

Intensive diabetes treatment used inappropriately in clinically complex type 2 diabetics

RelatedReports

Social networks play key roles in parental vaccination decisions
Infectious Disease

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

January 30, 2023
Romosozumab significantly increases bone mineral density in postmenopausal women
Chronic Disease

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

January 30, 2023
Resection of colorectal liver metastases may improve cost and longevity
Chronic Disease

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

January 30, 2023
Quick Take: State Gun Laws, Gun Ownership, and Mass Shootings in the US: Cross-Sectional Time Series
Pediatrics

Homicide deaths are on the rise for children living in the United States

January 30, 2023
Next Post
Type 2 diabetes associated with reduction in disability-free life years

Intensive diabetes treatment used inappropriately in clinically complex type 2 diabetics

Ultrasound enhances gastrointestinal absorption of drugs at low frequencies

Opioids for chronic non-cancer pain linked to increased mortality

Racial differences in colorectal cancer survival linked to health at initial diagnosis

Potential gene target identified for colorectal cancer treatment [PreClinical]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options